144 related articles for article (PubMed ID: 1887370)
1. Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation.
Bertagnolli MM; Herrmann SH; Pinto VM; Schoof DD; Eberlein TJ
Surgery; 1991 Sep; 110(3):459-68. PubMed ID: 1887370
[TBL] [Abstract][Full Text] [Related]
2. The role of T lymphocytes in the immunotherapy of tumours.
Brondz BD; Balashov KE
Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
4. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
5. Human tumor-infiltrating lymphocytes: a marker of host response.
Vose BM; Moore M
Semin Hematol; 1985 Jan; 22(1):27-40. PubMed ID: 3155876
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human cytotoxic lymphocytes directed against cells infected with typhus group rickettsiae: evidence for lymphokine activation of effectors.
Carl M; Dasch GA
J Immunol; 1986 Apr; 136(7):2654-61. PubMed ID: 3081648
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
8. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
9. Generation of antisuppressor T cells for alloreactive cytotoxic T lymphocytes.
Ting CC; Hargrove ME
J Immunol; 1987 Dec; 139(12):3964-72. PubMed ID: 2961802
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of cytotoxic lymphocytes potentially relevant for cellular immunotherapy of cancer: implications for designing clinical strategies.
Triebel F; Hercend T
Prog Clin Biol Res; 1987; 244():207-11. PubMed ID: 3498949
[No Abstract] [Full Text] [Related]
11. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy.
Sznol M; Urba WJ
Cancer Chemother Biol Response Modif; 1994; 15():213-25. PubMed ID: 7779587
[No Abstract] [Full Text] [Related]
13. Control mechanisms of cell-mediated reactions.
Salerno A; Sireci G; Dominici R; Bonanno CT; Caccamo N; Dieli F
Wien Klin Wochenschr; 1996; 108(8):244-7. PubMed ID: 8686315
[TBL] [Abstract][Full Text] [Related]
14. Cellular mechanisms of tumor rejection in rats.
Yamaki T; Uede T; Kikuchi K
Nat Immun Cell Growth Regul; 1990; 9(1):1-25. PubMed ID: 2184350
[TBL] [Abstract][Full Text] [Related]
15. Adoptive T-cell immunotherapy of cancer.
Li Q; Chang AE
Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
17. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
18. Cognate interactions between helper T cells and B cells. I. Cloning and helper activity of a lymphokine-dependent helper T cell clone (Th-3).
Noelle RJ; McCann J
J Mol Cell Immunol; 1989; 4(3):161-73; discussion 173-5. PubMed ID: 2527511
[TBL] [Abstract][Full Text] [Related]
19. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.
Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514
[TBL] [Abstract][Full Text] [Related]
20. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
